Vice President - Global Nucleic Acid Therapies Early Development Program Leader

About the Department

Dicerna, a Novo Nordisk company, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Our proprietary GalXC™ and GalXC-Plus™ RNAi technologies have the potential to address conditions that are difficult or impossible to treat with other modalities. Established as a Transformational Research Unit (TRU) following Novo Nordisk’s acquisition of Dicerna Pharmaceuticals, Inc. in December 2021, the Dicerna TRU is a unique new organization within Novo Nordisk that brings together the best of both worlds – the agility, collaborative pioneering spirit and calculated risk-taking profile of a biotech along with the scale, resources and capabilities of a global leader in drug development. With approximately 200 researchers, scientists, drug developers and operational staff, we are a team of inventive and entrepreneurial thinkers pushing the boundaries of science to create and drive new RNAi-based therapies for both rare and more prevalent diseases from the bench to the clinic. Together, we are driving change. Are you ready to make a difference?

 

The Position

The Vice President, Global Nucleic Acid Therapies Early Development Program Leader is titled internally as a Project Vice President (PVP).  The PVP is the leader of siRNA phase I development project Global Project Teams (GPT)/Core Groups constituted by key members from different areas across Novo Nordisk with specific skills ensuring that the product is optimally developed.

 

In agreement with the Head of Dicerna TRU Early Develpment and the relevant Therapy Area Corporate Vice President (CVP), the PVP is overall accountable to the relevant governance bodies for one or more drug development projects and is together with the GPT/Core Groups responsible for leading and managing the drug development process and meeting project goals and objectives. The PVP will be responsible for transitioning projects from Research PVPs prior to Phase I and to Development PVP's who will be responsible for Phase 2.

 

Relationships

Reports to the Head of Dicerna TRU Early Development. Main internal stakeholders include Dicerna Transformational Research Unit (TRU) and the Dicerna TRU Board, Boston Global Development, Global Translation, SciComm, EDComm, Product Development (PD) Committee, Research & Early Development (R&ED) Mgmt, ExecMgmt, and the SVP management groups across R&D.

 

External interactions include Health Authorities (e.g. EMA, FDA, CHMP, PMDA), Global Advisory Boards, Ethics Committees, Key Opinion Leaders, Investigators, CROs, vendors, in general world-wide. Proactive and responsible member of the Head of Dicerna TRU Early Development Leadership team.

 

The job function requires a very high degree of independence and decisions taken have a high degree of business impact. Independence and initiative should always be demonstrated when planning and prioritising tasks and be in accordance with Dicerna TRU and Novo Nordisk corporate goals and the current PDP as well as in accordance with Novo Nordisk clinical trial SOPs, applicable Novo Nordisk policies and “The Novo Nordisk Way”.

 

Essential Functions

• Managing and effectively driving drug development projects in accordance with the Novo Nordisk Global Project Framework
• Leading the core teams/GPTs, assuring performance and development of the team in agreement with the Head of Dicerna TRU Early Development
• Creating high performance project teams in line with the Novo Nordisk Way
• Accountable to the Head of Dicerna TRU Early Development and the relevant governance boards for the progress of the project(s) in accordance with the approved goals, agreed key deliverables, milestones and granted internal and external resources
• Responsible for the project budget and defined financial targets
• Ensuring that the drug development project strategies are set in accordance with the therapy areas and reflected in the Product Development Plan (PDP) in agreement with the Head of Dicerna TRU Early Development
• Driving the establishment, evaluation and recommendation of strategic options to maximise project value
• Responsible for internal and external project communication and intellectual property strategies in collaboration with the Head of Dicerna TRU Early Development
• Supports individual project team members to improve their current performance and future potential through providing coaching and development opportunities and provides regular feedback on project member performance to the relevant LoB

 

Physical Requirements

The PVP position is based in Greater Boston as part of the Dicerna TRU Early Development team and will interact with external advisors and regulatory authorities world-wide. Domest